This article was originally published in The Gray Sheet
Smith & Nephew will gain full control of the Dermagraft tissue-engineered dermal replacement product joint venture with Advanced Tissue Sciences via a proposed purchase of ATS' stake for $12 mil. ATS, which filed for Chapter 11 protection Oct. 10 in southern California federal bankruptcy court, expects to be advanced up to $5 mil. of the purchase price to continue operations until the sale is approved by the court. In addition to Dermagraft for diabetic foot ulcers, the deal includes TransCyte temporary skin cover for serious burns; combined sales are expected to reach $8 mil. this year, S&N says. Upon completion of the deal, S&N will become a contract manufacturer for non-wound care products retained by ATS. The companies will dissolve their NeoCyte human cartilage development joint venture...
You may also be interested in...
Smith & Nephew is attributing declining sales of its BoneCutter disposable arthroscopy blade sales in the first half of 2003 to increased reuse of the products following the enactment of the Medical Device User Fee & Modernization Act
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.